Northwest Bioth Cmn (NWBO): Price and Financial Metrics


Northwest Bioth Cmn (NWBO): $1.48

-0.06 (-3.90%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add NWBO to Watchlist
Sign Up

Industry: Biotech


Ranked

of 484

in industry

NWBO POWR Grades


  • NWBO scores best on the Sentiment dimension, with a Sentiment rank ahead of 54.28% of US stocks.
  • The strongest trend for NWBO is in Stability, which has been heading up over the past 31 weeks.
  • NWBO ranks lowest in Momentum; there it ranks in the 9th percentile.

NWBO Stock Summary

  • NWBO's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 0.03 -- higher than just 0.11% of US-listed equities with positive expected earnings growth.
  • NWBO's price/sales ratio is 1,374.92; that's higher than the P/S ratio of 99.23% of US stocks.
  • Over the past twelve months, NWBO has reported earnings growth of -8,574.34%, putting it ahead of just 0.19% of US stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Northwest Biotherapeutics Inc, a group of peers worth examining would be ARWR, HPK, NFE, GRWG, and MKL.
  • NWBO's SEC filings can be seen here. And to visit Northwest Biotherapeutics Inc's official web site, go to www.nwbio.com.

NWBO Stock Price Chart Interactive Chart >

Price chart for NWBO

NWBO Price/Volume Stats

Current price $1.48 52-week high $2.51
Prev. close $1.54 52-week low $0.26
Day low $1.48 Volume 1,545,605
Day high $1.56 Avg. volume 2,112,927
50-day MA $1.53 Dividend yield N/A
200-day MA $1.38 Market Cap 1.26B

Northwest Bioth Cmn (NWBO) Company Bio


Northwest Biotherapeutics is a biotechnology company focused on developing immunotherapy products to treat cancers more effectively than current treatments, without toxicities of the kind associated with chemotherapies. The company was founded in 1996 and is based in Bethesda, Maryland.


NWBO Latest News Stream


Event/Time News Detail
Loading, please wait...

NWBO Latest Social Stream


Loading social stream, please wait...

View Full NWBO Social Stream

Latest NWBO News From Around the Web

Below are the latest news stories about Northwest Biotherapeutics Inc that investors may wish to consider to help them evaluate NWBO as an investment opportunity.

UK Manufacturing Facility & Phase III Trial Updates From Northwest Biotherapeutics (OTCQB: NWBO)

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that an application for certification of the manufacturing facility in Sawston, UK has been submitted to the Medicines and Healthcare Products Regulatory Agency (MHRA). The Company also provided a process update on the DCVax®-L Phase III Trial.

Yahoo | May 12, 2021

Is Northwest Biotheraputics a Buy Ahead of Its Brain Tumor Vaccine Clinical Data Release?

In a short period of time, this immunotherapy biotech could either become a multi-bagger or trade near $0.

Yahoo | October 28, 2020

Northwest Biotherapeutics Announces Data Lock of Phase III Trial

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the database for the Phase III trial of DCVax®-L for Gliobastoma has been locked.

Yahoo | October 5, 2020

Northwest Biotherapeutics Acquires Flaskworks

Northwest Biotherapeutics (OTCQB: NWBO) ("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Company has acquired Flaskworks, a company that has developed a breakthrough system to close and automate the manufacturing of cell therapy products such as DCVax®.

Yahoo | September 1, 2020

Northwest Biotherapeutics Announces $8 Million Financing

Northwest Biotherapeutics (OTCQB: NWBO)("NW Bio"), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, today announced that the Company has completed a financing on favorable terms for approximately $8 million. The Company anticipates that this financing will help maintain the Company's momentum, and will provide some prudent protection in the midst of the current global economic uncertainties. The financing also further broadens the lock-up of warrants that the Company has been building.

Yahoo | August 11, 2020

Read More 'NWBO' Stories Here

NWBO Price Returns

1-mo -6.33%
3-mo -6.92%
6-mo 8.82%
1-year 291.53%
3-year 448.15%
5-year 138.71%
YTD -2.95%
2020 609.63%
2019 4.57%
2018 -12.63%
2017 -32.43%
2016 -89.12%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 1.6119 seconds.